FDA Reviews Moderna's Flu Vaccine Following Trump's Initial Refusal

The FDA reversed an earlier decision to review the messenger RNA influenza vaccine from Moderna after a refusal under Donald Trump.Shares in the biotechnology firm rose 8 percent following the announcement as the agency set a final decision deadline for August 5.Health Secretary Robert F. Kennedy Jr. has sought to limit messenger RNA technology, though officials stated the review will maintain rigorous safety standards.CEO Stéphane Bancel expressed confidence in the vaccine candidate while Moderna commits to additional clinical studies focused on older populations.